[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553553":3},{"organization":4,"outcomesModule":7,"designInfo":30,"detailedDescription":16,"studyPopulation":16,"armGroups":36,"interventions":42,"overallOfficials":16,"centralContacts":47,"locations":56,"responsibleParty":75,"collaborators":77,"id":81,"slug":16,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":16,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":89,"maxAge":16,"enrollmentInfo":90,"targetDuration":16,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":58,"whyStopped":16,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"University of Maryland St. Joseph Medical Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence of postoperative acute kidney injury, atrial fibrillation","The primary endpoint will be measured by comparing the incidence of new-onset atrial fibrillation or acute kidney injury","28 days",[14,17,19,21,23,25,28],{"measure":15,"description":16,"timeFrame":12},"Hours on Vasopressors",null,{"measure":18,"description":16,"timeFrame":12},"Total IVF",{"measure":20,"description":16,"timeFrame":12},"ICU LOS",{"measure":22,"description":16,"timeFrame":12},"Postoperative LOS",{"measure":24,"description":16,"timeFrame":12},"Any major STS complication",{"measure":26,"description":16,"timeFrame":27},"30-day mortality","30 days",{"measure":29,"description":16,"timeFrame":12},"Cost",{"allocation":31,"interventionModel":32,"interventionModelDescription":16,"primaryPurpose":33,"observationalModel":16,"timePerspective":16,"maskingInfo":34},"NA","SINGLE_GROUP","TREATMENT",{"masking":35,"maskingDescription":16,"whoMasked":16},"NONE",[37],{"label":38,"type":6,"description":39,"interventionNames":40},"Study Drug Arm - Angiotensin II arm","Angiotensin II",[41],"Drug: Angiotensin II",[43],{"type":44,"name":39,"description":45,"armGroupLabels":46,"otherNames":16},"DRUG","Angiotensin II: Starting dose of 2.5 ng\u002Fkg\u002Fmin administered IV; may dose escalate up to 80 ng\u002Fkg\u002Fmin in order to achieve a MAP of 65 mmHg or higher in the first 3 hours. After 3 hours, may escalate dose up to 40 ng\u002Fkg\u002Fmin in order to achieve a MAP of 65 mmHg. Dose titration in increments of 10 ng\u002Fkg\u002Fmin every 2 minutes.",[38],[48,53],{"name":49,"role":50,"phone":51,"phoneExt":16,"email":52},"Aja Janyavula","CONTACT","410-427-5459","ajanyavula@umm.edu",{"name":54,"role":50,"phone":51,"phoneExt":16,"email":55},"Sam Rudow","samuel.rudow@umm.edu",[57],{"facility":5,"status":58,"city":59,"state":60,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"RECRUITING","Towson","Maryland","21204","United States","US",{"type":65,"coordinates":66},"Point",[67,68],-76.60191,39.4015,{"lat":68,"lon":67},[71,72],{"name":54,"role":50,"phone":51,"phoneExt":16,"email":55},{"name":73,"role":74,"phone":16,"phoneExt":16,"email":16},"Rawn Salenger, MD","PRINCIPAL_INVESTIGATOR",{"type":76,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR",[78],{"name":79,"class":80},"La Jolla Pharmaceutical Company","INDUSTRY","100553553",false,"NCT06487585","ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)","Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery (ANG-First Trial)","Inclusion Criteria:\n\n* Adult patients ≥ 18 years of age undergoing cardiac surgery requiring CPB\n* Patients must have clinical features of vasodilation as determined by a MAP \\\u003C 65 mmHg that is non-transient in the opinion of the treating physician\n* Patients must be adequately volume resuscitated in the opinion of the treating physician\n* Systemic Vascular Resistance index (SVRi) \\\u003C 1970 dynes·sec\u002Fcm⁵\u002Fm² to support the clinical diagnosis of vasodilation; if no pulmonary artery catheter is in place, vasodilatory hypotension diagnosis according to the judgement of the critical care team\n* Biventricular systolic function is at or greater than pre-cardiopulmonary bypass baseline as demonstrated by echocardiographic evaluation, or the patient is concomitantly treated with\n\nExclusion Criteria:\n\n* Bleeding as primary etiology of hypotension, as determined by \\> 4 units RBC transfusion in 24 hours.\n* Patients on ECMO\n* Patients with active endocarditis\n* Patients already on renal replacement therapy or creatinine of \\> 4 mg\u002Fdl within 2 weeks of surgery\n* Patients with contraindications to Angiotensin II including women who are pregnant or breastfeeding or have active coronary ischemia, mesenteric ischemia, limb ischemia, or high potassium (\\> 5.5 meq\u002FL) while receiving Angiotensin II",true,"ALL","18 Years",{"count":91,"type":92},100,"ESTIMATED","INTERVENTIONAL",[95],"PHASE4","The purpose of this research is to evaluate the use of Angiotensin II in patients with low blood pressure post-surgery. Your information will be collected for 28 days post the procedure and initiation of the study drug to assess for safety events and complications.",[98],"Vasodilatory Hypotension During or After Cardiac Surgery",[100,101,102,103],"Vasodilation","Hypotension","Cardiopulmonary Bypass","Cardiac Surgery","2025-12-18",{"date":106,"type":107},"2025-12-22","ACTUAL",{"date":109,"type":107},"2025-05-06",{"date":111,"type":92},"2026-02",{"name":5,"class":6},1]